Skip to content
Adrienne Monson – Lifestyle
Author:
Kalaris Therapeutics, Inc.
Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
November 10, 2026
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
August 31, 2026
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 11, 2026
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
July 20, 2026
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
July 17, 2026
Kalaris Appoints Laurie Keating to Board of Directors
July 6, 2026
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
June 23, 2026
Kalaris to Present at Clinical Trials at the Summit 2026
June 12, 2026